Do children with stable asthma benefit from addition of montelukast to inhaled corticosteroids: Randomized, placebo controlled trial

Conclusion It is reasonable to add montelukast to ICS therapy in asthmatic children during the school year, to lower cumulative ICS dose in children with well controlled asthma symptoms, as well as to reduce number of exacerbations, and to achieve better control of EIB. Trial registration NCT01266772.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research